ProShare Advisors’s OptimizeRx OPRX Stock Holding History

ProShare Advisors’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,312	Closed	-$269K	–	2271
2021 Q4	$269K	Buy	+4,312	New	+$327K	﹤0.01%	1850
2021 Q3	–	Sell	-4,370	Closed	-$271K	–	2184
2021 Q2	$271K	Buy	4,370 +9	+0.2%	+$458	﹤0.01%	1959
2021 Q1	$213K	Buy	+4,361	New	+$210K	﹤0.01%	2004

Other funds holding OPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

GIPM

G2 Investment Partners Management New York $549M AUM 179.59% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return

ProShare Advisors's OPRX Position: Q1 2022 in Review

ProShare Advisors sold out of OptimizeRx (OPRX) in Q1 2022, closing a stake of 4,312 shares — an estimated $269K sold.

ProShare Advisors first reported a position in OPRX in Q1 2021 and held it in 3 quarters. The position peaked at $271K in Q2 2021. 153 funds tracked by Wall St. Rank hold OPRX as of Q1 2022.

ProShare Advisors reported no remaining OptimizeRx position as of Q1 2022 after selling out during the quarter.
ProShare Advisors sold 4,312 OptimizeRx shares in Q1 2022, an estimated $269K.
ProShare Advisors first reported a position in OptimizeRx in Q1 2021 and held it in 3 quarters.
ProShare Advisors's OptimizeRx position peaked at $271K in Q2 2021.
153 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2022.

Based on ProShare Advisors's 13F filing for Q1 2022, filed 10 May 2022.